Zero Candida Ltd (TSX-V:ZCT, OTCQB:ZCTFF) announced that its common shares are now eligible for Depository Trust Company (DTC) electronic clearing and settlement services.
DTC eligibility allows for electronic clearing and settlement of Zero Candida’s common shares in the United States.
The FemTech medical device company focused on women’s health said this will improve trading efficiency, reduce settlement times, enhance liquidity, lower transaction costs, and increase accessibility to a broader range of US investors, including institutions requiring DTC eligibility for investment consideration.
The company also said it will present at the OTCQB Venture Virtual Investor Conference on August 7.
"Achieving DTC eligibility represents a significant advancement in our capital markets strategy, providing enhanced liquidity and accessibility for our US investors,” Zero Candida CEO Eli Ben Haroosh said in a statement.
“Combined with our participation in the upcoming OTCQB Venture Virtual Investor Conference, we are positioned to reach a broader institutional and retail investor audience as we unlock value through AI-driven medical technology."